Potential acute myeloid leukemia treatment receives Rare Pediatric Disease Designation
SLS009 (SELLAS Life Sciences) has been granted Rare Pediatric Disease Designation by the FDA for the treatment of pediatric acute myeloid leukemia (AML), according to a press release from SELLAS Life Sciences Group.1 The highly selective CDK9 inhibitor was …